Trexquant Investment LP Has $5.57 Million Holdings in Natera, Inc. (NASDAQ:NTRA)

Trexquant Investment LP trimmed its holdings in Natera, Inc. (NASDAQ:NTRA - Free Report) by 44.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 35,174 shares of the medical research company's stock after selling 27,787 shares during the period. Trexquant Investment LP's holdings in Natera were worth $5,568,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Principal Securities Inc. increased its stake in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Gladstone Institutional Advisory LLC increased its position in shares of Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock worth $574,000 after acquiring an additional 61 shares in the last quarter. Silver Oak Securities Incorporated raised its holdings in shares of Natera by 3.1% during the fourth quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock worth $470,000 after acquiring an additional 89 shares during the period. Blue Trust Inc. lifted its position in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. Finally, Hanseatic Management Services Inc. boosted its stake in Natera by 12.0% in the 4th quarter. Hanseatic Management Services Inc. now owns 998 shares of the medical research company's stock worth $158,000 after purchasing an additional 107 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Remove Ads

Natera Stock Performance

NTRA stock traded down $11.45 during trading hours on Thursday, hitting $140.52. 697,872 shares of the stock were exchanged, compared to its average volume of 1,387,802. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $19.00 billion, a P/E ratio of -79.75 and a beta of 1.80. The company has a 50-day simple moving average of $153.85 and a two-hundred day simple moving average of $151.75.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. On average, analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on NTRA. JPMorgan Chase & Co. increased their price objective on Natera from $160.00 to $200.00 and gave the stock an "overweight" rating in a report on Friday, December 13th. BTIG Research reaffirmed a "buy" rating on shares of Natera in a research note on Friday, February 28th. Robert W. Baird increased their target price on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a report on Friday, February 28th. Sanford C. Bernstein raised their target price on shares of Natera from $160.00 to $200.00 and gave the company an "outperform" rating in a research report on Friday, January 10th. Finally, StockNews.com raised shares of Natera from a "sell" rating to a "hold" rating in a research report on Wednesday, March 19th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $175.76.

Insider Buying and Selling at Natera

In related news, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction that occurred on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the sale, the chief executive officer now owns 267,629 shares in the company, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Michael Burkes Brophy sold 946 shares of the business's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $171.98, for a total transaction of $162,693.08. Following the transaction, the chief financial officer now owns 109,474 shares of the company's stock, valued at approximately $18,827,338.52. This represents a 0.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 325,922 shares of company stock valued at $51,603,664 in the last three months. Corporate insiders own 7.60% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.